Innovent Biologics (IVBXF) News Today $9.74 0.00 (0.00%) As of 06/20/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock IVBXF Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific SessionsJune 21 at 9:35 PM | prnewswire.comInnovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in ChinaJune 15, 2025 | prnewswire.comInnovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific SessionsJune 12, 2025 | prnewswire.comInnovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung CancerJune 4, 2025 | prnewswire.com2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung CancerJune 3, 2025 | prnewswire.comASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic CancerJune 2, 2025 | prnewswire.com2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid TumorsJune 2, 2025 | prnewswire.com2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal CancerJune 1, 2025 | prnewswire.comASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant MelanomaMay 31, 2025 | prnewswire.comInnovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 AntibodiesMay 28, 2025 | prnewswire.comInnovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global InnovationMay 18, 2025 | prnewswire.comBispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular EdemaMay 6, 2025 | prnewswire.comInnovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025May 5, 2025 | prnewswire.comInnovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced MalignanciesApril 29, 2025 | prnewswire.com2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCsApril 27, 2025 | prnewswire.comInnovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung CancerApril 25, 2025 | prnewswire.comSeven Oral Presentations: Innovent to Present Breakthrough Clinical Data of IBI363（PD-1/IL-2α-bias）and Other Novel Drug Candidates at the 2025 ASCO Annual MeetingApril 23, 2025 | prnewswire.com3 Asian Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.6%April 6, 2025 | finance.yahoo.comJ.P. Morgan Sticks to Their Buy Rating for Innovent Biologics (IVBXF)April 2, 2025 | markets.businessinsider.comInnovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in MelanomaMarch 30, 2025 | prnewswire.comInnovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual MeetingMarch 26, 2025 | prnewswire.comInnovent Announces 2024 Annual Results and Business UpdatesMarch 26, 2025 | prnewswire.comInnovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian CancerMarch 23, 2025 | prnewswire.comHigh Growth Tech Stocks In Asia To Watch March 2025March 17, 2025 | finance.yahoo.comInnovent Biologics’ SYCUME® Gains Approval as China’s First IGF-1R Antibody for Thyroid Eye DiseaseMarch 14, 2025 | msn.comChina's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye DiseaseMarch 14, 2025 | prnewswire.comInnovent Is Said to Consider Licensing Partnership for Cancer DrugMarch 11, 2025 | bloomberg.comHead-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in MelanomaMarch 2, 2025 | prnewswire.comNMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon CancerFebruary 23, 2025 | prnewswire.comInnovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung CancerFebruary 16, 2025 | prnewswire.comExploring High Growth Tech And 2 Other Prominent Stocks With PotentialFebruary 6, 2025 | uk.finance.yahoo.comInnovent Biologics: Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung CancerJanuary 18, 2025 | finanznachrichten.deInnovent & ASK Pharm Announce NMPA Approval Of Limertinib,3rd-Gen EGFR TKI For Lung Cancer TreatmentJanuary 16, 2025 | markets.businessinsider.comInnovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung CancerJanuary 16, 2025 | prnewswire.comInnovent Presents at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 16, 2025 | prnewswire.comInnovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic CancerJanuary 15, 2025 | prnewswire.comHigh Growth Tech Stocks Innovent Biologics And 2 Other Promising PicksJanuary 9, 2025 | finance.yahoo.comInnovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2025 | prnewswire.comInnovent wins second China nod for Nuvation-partnered cancer therapyJanuary 3, 2025 | msn.comInnovent Biologics: Strategic Partnerships and Robust Pipeline Drive Buy RatingJanuary 3, 2025 | markets.businessinsider.comRoche, Innovent ink licensing deal for lung cancer drugJanuary 2, 2025 | msn.comInnovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland ChinaDecember 16, 2024 | finance.yahoo.comInnovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024December 8, 2024 | prnewswire.comHUTCHMED Gains Approval for Innovative Cancer TherapyDecember 4, 2024 | msn.comInnovent Biologics Secures New Approval for Cancer TreatmentDecember 4, 2024 | markets.businessinsider.comInnovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug ListNovember 27, 2024 | prnewswire.comInnovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024November 24, 2024 | prnewswire.comClaudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial ProgressNovember 22, 2024 | globenewswire.comInnovent Ditches Low-Value Stake Sale After Investor OutcryNovember 7, 2024 | benzinga.comInnovent Biologics Inc.November 6, 2024 | wsj.com Get Innovent Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter. Email Address IVBXF Media Mentions By Week IVBXF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVBXF News Sentiment▼0.000.67▲Average Medical News Sentiment IVBXF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVBXF Articles This Week▼21▲IVBXF Articles Average Week Get Innovent Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ASPHF News Today ASCLF News Today AVCTF News Today AWKNF News Today BRRGF News Today BCTXW News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IVBXF) was last updated on 6/22/2025 by MarketBeat.com Staff From Our PartnersGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovent Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovent Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IVBXF Stock Free IVBXF Stock Alerts